Dietmar Rudolf Thal1, Thomas G Beach2, Michelle Zanette3, Kerstin Heurling4, Aruna Chakrabarty5, Azzam Ismail5, Adrian P L Smith6, Christopher Buckley6. 1. Institute of Pathology-Laboratory of Neuropathology, Center for biomedical Research, University of Ulm, Ulm, Germany. Electronic address: dietmar.thal@uni-ulm.de. 2. Civin Laboratory for Neuropathology, Banner Sun Health Research Institute, Sun City, AZ, USA. 3. Life Sciences R&D Biometrics, GE Healthcare, Princeton, NJ, USA. 4. Life Sciences R&D, GE Healthcare, Uppsala, Sweden; Department of Surgical Sciences: Radiology, Uppsala University, Uppsala, Sweden. 5. Pathology and Tumour Biology, Leeds Institute of Molecular Medicine, St. James Hospital, Leeds, UK. 6. Life Sciences R&D, GE Healthcare, Amersham, UK.
Abstract
BACKGROUND: Amyloid positron emission tomography (PET) has become an important tool to identify amyloid-β (Aβ) pathology in Alzheimer's disease (AD) patients. Here, we determined the diagnostic value of the amyloid PET tracer [(18)F]flutemetamol in relation to Aβ pathology at autopsy. METHODS: [(18)F]flutemetamol PET was carried out in a cohort of 68 patients included in a [(18)F]flutemetamol amyloid PET imaging end-of-life study (GE067-007). At autopsy, AD pathology was determined and Aβ plaque pathology was classified into phases of its regional distribution (0-5). RESULTS: [(18)F]flutemetamol PET was universally positive in cases with advanced stage postmortem Aβ pathology (Aβ phases 4 and 5). Negative amyloid PET was universally observed in nondemented or non-AD dementia cases with initial Aβ phases 1 and 2, whereas 33.3% of the phase 3 cases were positive. CONCLUSIONS: [(18)F]flutemetamol amyloid PET detects primarily advanced stages of Aβ pathology in preclinical and symptomatic AD cases.
BACKGROUND: Amyloid positron emission tomography (PET) has become an important tool to identify amyloid-β (Aβ) pathology in Alzheimer's disease (AD) patients. Here, we determined the diagnostic value of the amyloid PET tracer [(18)F]flutemetamol in relation to Aβ pathology at autopsy. METHODS: [(18)F]flutemetamol PET was carried out in a cohort of 68 patients included in a [(18)F]flutemetamol amyloid PET imaging end-of-life study (GE067-007). At autopsy, AD pathology was determined and Aβ plaque pathology was classified into phases of its regional distribution (0-5). RESULTS: [(18)F]flutemetamol PET was universally positive in cases with advanced stage postmortem Aβ pathology (Aβ phases 4 and 5). Negative amyloid PET was universally observed in nondemented or non-AD dementia cases with initial Aβ phases 1 and 2, whereas 33.3% of the phase 3 cases were positive. CONCLUSIONS: [(18)F]flutemetamol amyloid PET detects primarily advanced stages of Aβ pathology in preclinical and symptomatic AD cases.
Authors: Arno de Wilde; Wiesje M van der Flier; Wiesje Pelkmans; Femke Bouwman; Jurre Verwer; Colin Groot; Marieke M van Buchem; Marissa Zwan; Rik Ossenkoppele; Maqsood Yaqub; Marleen Kunneman; Ellen M A Smets; Frederik Barkhof; Adriaan A Lammertsma; Andrew Stephens; Erik van Lier; Geert Jan Biessels; Bart N van Berckel; Philip Scheltens Journal: JAMA Neurol Date: 2018-09-01 Impact factor: 18.302
Authors: Alberto Serrano-Pozo; Jing Qian; Alona Muzikansky; Sarah E Monsell; Thomas J Montine; Matthew P Frosch; Rebecca A Betensky; Bradley T Hyman Journal: J Neuropathol Exp Neurol Date: 2016-04-22 Impact factor: 3.685
Authors: Soo Hyun Cho; Jeong-Hyeon Shin; Hyemin Jang; Seongbeom Park; Hee Jin Kim; Si Eun Kim; Seung Joo Kim; Yeshin Kim; Jin San Lee; Duk L Na; Samuel N Lockhart; Gil D Rabinovici; Joon-Kyung Seong; Sang Won Seo Journal: Eur J Nucl Med Mol Imaging Date: 2018-07-06 Impact factor: 9.236
Authors: Janusch Blautzik; Matthias Brendel; Julia Sauerbeck; Sebastian Kotz; Franziska Scheiwein; Peter Bartenstein; John Seibyl; Axel Rominger Journal: Eur J Nucl Med Mol Imaging Date: 2017-03-22 Impact factor: 9.236
Authors: Christopher Breault; Jonathan Piper; Abhinay D Joshi; Sara D Pirozzi; Aaron S Nelson; Ming Lu; Michael J Pontecorvo; Mark A Mintun; Michael D Devous Journal: Am J Nucl Med Mol Imaging Date: 2017-07-15
Authors: Clifford R Jack; Heather J Wiste; Stephen D Weigand; Terry M Therneau; Val J Lowe; David S Knopman; Jeffrey L Gunter; Matthew L Senjem; David T Jones; Kejal Kantarci; Mary M Machulda; Michelle M Mielke; Rosebud O Roberts; Prashanthi Vemuri; Denise A Reyes; Ronald C Petersen Journal: Alzheimers Dement Date: 2016-09-30 Impact factor: 21.566